Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866930 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 3
- Development phase
- 453
- Enrollment target
NCT01866930: Clinical Trial Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT01866930 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 453 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01866930, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 453 participants
- Enrollment target
Study Summary
To evaluate Sustained Virologic Response at post treatment Week 12 (SVR12)following treatment with Lambda/RBV/DCV in chronic HCV GT-1, -2, -3 or -4 subjects co-infected with HIV-1
Primary Outcome
SVR12 was defined as HCV RNA less than lower limit of quantification (\< LLOQ) (25 IU/mL; target detected or not detected) at follow-up week 12.
Interventions
- DRUG Daclatasvir (DCV)
- BIOLOGICAL Pegylated Interferon Lambda-1a
- DRUG Ribasphere (RBV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2013-07-11 |
| Est. Completion | 2015-08-27 |
| Phase | Phase 3 |
Why NCT01866930 stopped before completion
NCT01866930 is an interventional study that assigns participants to a tested intervention. The registered 453 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 3 interventions - of which Daclatasvir (DCV) is the first listed.
NCT01866930 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01866930 about?
NCT01866930 is a clinical study titled "Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV". To evaluate Sustained Virologic Response at post treatment Week 12 (SVR12)following treatment with Lambda/RBV/DCV in chronic HCV GT-1, -2, -3 or -4 subjects co-infected with HIV-1
What is the current status of trial NCT01866930?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 453 participants. The study started on 2013-07-11. Estimated completion is 2015-08-27.
What interventions are being tested in trial NCT01866930?
The interventions under investigation include: Daclatasvir (DCV) (DRUG), Pegylated Interferon Lambda-1a (BIOLOGICAL), Ribasphere (RBV) (DRUG).
Who is sponsoring clinical trial NCT01866930?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01866930's enrollment target sits among peer trials
453 834th of 2000 higher than 1,166 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03460977 · 453 participants · Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- NCT04708171 · 453 participants
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
- NCT05489211 · 454 participants · Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- NCT05655936 · 454 participants · NA
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI